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OBJECTIVES: Monitoring of Neoral by 2-hour post-dose
cyclosporine (CsA) levels (C2) is an accurate measure of CsA
absorption efﬁciency and exposure. It is superior to trough (C0)
monitoring for prediction of rejection risk and for targeting
optimal CsA doses. Our goal was to assess potential economic
beneﬁts of C2 monitoring by the use of an economic model.
METHODS: Parameter estimates for key clinical events were
derived from two cohorts containing 296 patients for C2 moni-
toring and 204 for C0 monitoring. An economic model was
developed to calculate treatment costs according to different clin-
ical outcomes. This multiple regression model is based on
resource utilization records of kidney transplanted patients at
Medizinische Hochschule Hannover. RESULTS: The incidence of
clinically conﬁrmed acute rejection (CAR) at 3 months post-
transplant was 28.2% for patients monitored by C0 and 15.3%
for C2. Delayed graft function (DGF) and graft failure occurred
in 32.4% and 4.4% of the C0 population and 36.5% and 4.9%
of the C2 population, respectively. These events resulted in a
highly signiﬁcant increment on 3-months treatment costs, i.e.
5424€ (DGF), 6362€ (CAR) and 14,117€ (graft failure) com-
pared to problem-free patients. Average direct three-months
treatment costs were 22,583€ for C0 and 20,650€ for C2
cohorts. CONCLUSION: Use of C2 monitoring produces not
only clinically important beneﬁts but also provides an estimated
saving of 1933€ during the ﬁrst 3 months after transplantation.
Therefore, C2 promises to be a superior patient management
strategy over C0 monitoring. The model developed allows a pre-
liminary assessment of the short-term economic impact of C2
monitoring.
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OBJECTIVES: Immunosuppresive therapy is required to prevent
graft rejection. Older medicines such as tacrolimus are para-
doxically toxic to the kidney, whereas newer therapies such as
sirolimus (Rapamune) are not. The purpose of this study was to
evaluate the relative cost-utility of sirolimus versus tacrolimus in
the UK. METHODS: A stochastic simulation model was con-
structed using clinical trial and real-life data comparing the two
treatments. Time duration was up to 20-years, 2003 prices, dis-
counted at 6% for costs and 1.5% beneﬁts and from an NHS
perspective. Simulated events included patient and graft survival,
haemodialysis, peritoneal dialysis, re-transplants and acute rejec-
tion. Costs were summed for events and various maintenance
therapies. Utility was differentially accredited depending upon
survival using the alternative renal replacement therapies.
Outcome was predicted using post-transplant creatinine levels up
to 3-years. Extensive statistical economic analysis and sensitiv-
ity analysis was undertaken. RESULTS: Extensive validation
demonstrated that the simulation was very reliable. Over the 10-
year horizon, sirolimus gained 0.58yrs (discounted) of function-
ing graft over tacrolimus, resulting in an incremental cost per
year of functioning graft that was dominant (ICER was calcu-
lated at -£39,576). Over a 20-year time horizon cost effective-
ness of sirolimus over tacrolimus further improved with an
average discounted gain in years of a functioning graft of 1.5yrs,
resulting in an incremental cost-utility that was dominant (ICUR
-£46,695). The number of haemodialysis events was 48,243 on
sirolimus versus 127,829 129, on tacrolimus and peritoneal dial-
ysis events 40,872 versus 105,249, respectively. Sirolimus
remained dominant over tacrolimus under all scenarios. This
ﬁndings were robust using statistical economic analysis and sen-
sitivity analysis. CONCLUSIONS: Sirolimus was far more cost-
effective than tacrolimus and was economically “dominant”.
The magnitude of this difference indicates that this ﬁnding is
likely to be geographically generalisable.
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OBJECTIVES: An important complication of Benign Prostate
Hyperplasia is Acute Urinary Retention (AUR). This condition
needs acute catheterisation and is a predisposing factor for
surgery. Subsequent removal of the catheter is only possible in a
minority of patients. Moreover, after removing the catheter the
long-term prostatectomy rate is considerable. Alfuzosin increases
the success rate of catheter removal, and may decrease the need
for future surgery. This study assessed the cost-consequences of
treating patients with AUR with alfuzosin, watchful waiting or
immediate prostatectomy from the perspective of the National
Health Service (NHS) in the UK. METHODS: Starting from the
treatment path and the immediate and 6-month clinical outcome
of the trial programme “ALFAUR”, a medical decision model to
compare the cost-consequences of watchful waiting, immediate
prostatectomy and alfuzosin treatment was built in Excel MS
2000. The time horizon of the model was 6 months. Cost data
were obtained from the NHS and resource use data gathered
alongside the clinical trial. A Monte Carlo analysis, allowing
variability in all uncertain parameters of the model, was per-
formed to calculate the uncertainty surrounding the results. The
unit cost of alfuzosin was £0.79. Patients were continued on alfu-
zosin for 6 months if the catheter was removed successfully.
RESULTS: Treating patients with alfuzosin during initial hospi-
talisation for AUR and during the 6 months of follow-up after
successful catheter removal generates a cost-saving of £350
(CONF INT) relative to placebo and £892 (CONF INT) relative
to immediate prostatectomy. Both savings are statistically signif-
icant. Alfuzosin treatment was associated with a lower rate of
prostatectomy after discharge with a successful catheter removal.
CONCLUSIONS: Treating all patients hospitalised with AUR
with alfuzosin decreases the need for surgery and leads to impor-
tant savings for the public health care payer. Future studies
should explore the QoL outcomes of the different strategies.
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